Traders should risk a close below $105.
Buy BSX on any shallow dip towards $22.
Point and figure price projections measure as high as $188 for ZBH.

Ardelyx Has Big Potential Real Money Pro($)

This small-cap company's shares are half where they ended 2015.
This well-managed biotech company is trading for its lowest price/earnings multiple ever.
This is because they would buy more of the winning stocks lower.
The healthy sideways action over the last six weeks has worked off the name's overbought condition.
LH's $5.7B Covance takeover could be just what the doctor ordered.
These mid-caps would do well by themselves, but could tempt bigger companies.
Our quantitative service has upgraded the drug maker to a buy, but the technicals are not ready yet to join in.

Columnist Conversations

The stock and bond markets have been as close to being "closed" as they can get while the lights are still on....
Since its recovery-rally high at 101 last Thursday, Apple Inc. (AAPL) has given back about 40% of the entire u...
View Chart »  View in New Window » I like GDX on the buy side as long as we can hold ab...
First off, GILD was an unmitigated disaster, we cut this and ran. this is ugly here, we'll take this off...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.